Mycobacteria species other than Mycobacterium tuberculosis and M. leprae are responsible for nontuberculous mycobacterial (NTM) infections. These environmental bacteria frequently infects individuals with compromised immune systems or long-term lung conditions, infecting the lungs, lymph nodes, skin, and soft tissues. Skin ulcers, exhaustion, weight loss, and a persistent cough are some of the symptoms. Imaging and cultures are necessary for diagnosis. To guarantee recovery and avoid resistance, treatment entails lengthy multi-drug antibiotic regimens that can continue anywhere from months to years, occasionally in conjunction with surgery. The nontuberculous mycobacterial infections pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the nontuberculous mycobacterial infections pipeline analysis include Insmed Incorporated, Janssen Pharmaceutical K.K., and AN2 Therapeutics, Inc., among others.
Leading drugs currently in the pipeline include ALIS, Bedaquiline, and others.
Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Nontuberculous Mycobacterial Infections Pipeline Analysis Report by Expert Market Research gives comprehensive insights into nontuberculous mycobacterial infections therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for nontuberculous mycobacterial infections. The nontuberculous mycobacterial infections report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The nontuberculous mycobacterial infections pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with nontuberculous mycobacterial infections treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to nontuberculous mycobacterial infections.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Environmental exposure to species like Mycobacterium avium complex, which defy host defenses by limiting phagosome development and resisting oxidative stress, can result in nontuberculous mycobacterial (NTM) infections. Bacterial clearance is hampered by host vulnerability, which includes weakened immunity (such as abnormalities in the IFN-γ/IL-12 pathways) or structural lung injury (such as bronchiectasis). Granuloma growth, airway damage, and symptoms like cough and exhaustion are caused by chronic inflammation brought on by a persistent infection. Prolonged use of antibiotics that target intracellular bacteria is necessary for treatment.
Nontuberculous mycobacterial (NTM) infections are usually treated with a long-term combination antibiotic regimen that is specific to the NTM species. A macrolide (clarithromycin or azithromycin), ethambutol, and rifampin or rifabutin are frequently included in regimens for Mycobacterium avium complex (MAC). These medications are given daily or three times a week for a year following sputum culture conversion. In severe situations, injectable streptomycin or amikacin may be added first. The average course of treatment lasts 12 to 24 months. For complex, resistant, or localized pulmonary illness, surgery may be an option. Throughout treatment, it is crucial to keep an eye out for drug toxicity.
Nontuberculous mycobacterial (NTM) infections are becoming more common, particularly in individuals with non-cystic fibrosis bronchiectasis, where the frequency is approximately 10%. In the United States, the overall rate of NTM pulmonary disease increased from about 2.4 cases per 100,000 in the 1980s to over 15 cases per 100,000 by 2013. Regional rates are influenced by geography and environmental factors, and prevalence is higher in women and older people. Globally, including in Asia, Europe, and North America, rising patterns are being recorded.
This section of the report covers the analysis of nontuberculous mycobacterial infections drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, in the nontuberculous mycobacterial infections pipeline, maximum candidates are concentrated in Phase III with 60% of the projects followed by Phase II. Thus, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
The drug molecule categories covered under the nontuberculous mycobacterial infections pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. The nontuberculous mycobacterial infections report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for nontuberculous mycobacterial infections.
The EMR report for the nontuberculous mycobacterial infections pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in nontuberculous mycobacterial infections clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for nontuberculous mycobacterial infections. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of nontuberculous mycobacterial infections drug candidates.
Insmed Incorporated created Amikacin Liposome Inhalation Suspension (ALIS), an inhaled liposomal formulation of amikacin intended to treat lung illness caused by the refractory Mycobacterium avium complex (MAC). High quantities of amikacin are delivered straight to the lungs by ALIS, which is administered via the LamiraTM nebulizer. This improves absorption into macrophages and allows it to penetrate biofilms. Adults with treatment-refractory MAC lung infections are being evaluated for safety and effectiveness as a supplement to guideline-based therapy in the current Phase III trial.
The diarylquinoline antimycobacterial drug bedaquiline, created by Janssen Pharmaceutical K.K., prevents mycobacteria from producing energy by blocking their ATP synthase. Its effectiveness against nontuberculous mycobacterial (NTM) infections is being studied, despite the fact that it is licensed for multidrug-resistant tuberculosis (MDR-TB). In order to determine bedaquiline's safety and efficacy in treating treatment-refractory Mycobacterium avium complex lung illness, the ongoing Phase III trial assesses the medication in combination with clarithromycin and ethambutol.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share